These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 27259298)

  • 21. Metabolic and antihypertensive effects of moxonidine and moxonidine plus irbesartan in patients with type 2 diabetes mellitus and mild hypertension: a sequential, randomized, double-blind clinical trial.
    Derosa G; Cicero AF; D'Angelo A; Fogari E; Salvadeo S; Gravina A; Ferrari I; Fassi R; Fogari R
    Clin Ther; 2007 Apr; 29(4):602-10. PubMed ID: 17617283
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Microvascular disease: what does the UKPDS tell us about diabetic nephropathy?
    Bilous R
    Diabet Med; 2008 Aug; 25 Suppl 2():25-9. PubMed ID: 18717975
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oxidative stress and nitric oxide synthase in rat diabetic nephropathy: effects of ACEI and ARB.
    Onozato ML; Tojo A; Goto A; Fujita T; Wilcox CS
    Kidney Int; 2002 Jan; 61(1):186-94. PubMed ID: 11786100
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative effect of lisinopril and lacidipine on urinary albumin excretion in patients with type 11 diabetic nephropathy.
    Salako BL; Finomo FO; Kadiri S; Arije A; Olatosin AO
    Afr J Med Med Sci; 2002 Mar; 31(1):53-7. PubMed ID: 12518931
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A renoprotective effect of low dose losartan in patients with type 2 diabetes.
    Sawaki H; Terasaki J; Fujita A; Nakagawa S; Kanatsuna N; Sadahiro K; Isotani H; Imagawa A; Hanafusa T
    Diabetes Res Clin Pract; 2008 Jan; 79(1):86-90. PubMed ID: 17889959
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Renal protection and angiotensin converting enzyme inhibition in microalbuminuric type I and type II diabetic patients.
    Cooper ME
    J Hypertens Suppl; 1996 Dec; 14(6):S11-4. PubMed ID: 9023709
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Difficulties in reaching therapeutic goals for hypertension and dysplipidaemia in patients with type 2 diabetes in general practice.
    Knudsen ST; Mosbech TH; Hansen B; Kønig E; Johnsen PC; Kamper AL
    Dan Med J; 2013 Dec; 60(12):A4740. PubMed ID: 24355449
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Determinants of progression from microalbuminuria to proteinuria in patients who have type 1 diabetes and are treated with angiotensin-converting enzyme inhibitors.
    Ficociello LH; Perkins BA; Silva KH; Finkelstein DM; Ignatowska-Switalska H; Gaciong Z; Cupples LA; Aschengrau A; Warram JH; Krolewski AS
    Clin J Am Soc Nephrol; 2007 May; 2(3):461-9. PubMed ID: 17699452
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Renal function preservation in type 2 diabetes mellitus patients with early nephropathy: a comparative prospective cohort study between primary health care doctors and a nephrologist.
    Martínez-Ramírez HR; Jalomo-Martínez B; Cortés-Sanabria L; Rojas-Campos E; Barragán G; Alfaro G; Cueto-Manzano AM
    Am J Kidney Dis; 2006 Jan; 47(1):78-87. PubMed ID: 16377388
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Blood pressure goal attainment according to JNC 7 guidelines and utilization of antihypertensive drug therapy in MCO patients with type 1 or type 2 diabetes.
    Andros V; Egger A; Dua U
    J Manag Care Pharm; 2006 May; 12(4):303-9. PubMed ID: 16792436
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treating proteinuria in a diabetic patient despite hyperkalaemia due to hyporeninaemic hypoaldosteronism.
    van Nieuwkoop C; Ijpelaar DH; Bolk JH
    Neth J Med; 2007 Feb; 65(2):75-7. PubMed ID: 17379933
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Angiotensin receptor blocker and N-acetyl cysteine for reduction of proteinuria in patients with type 2 diabetes mellitus.
    Rasi Hashemi S; Noshad H; Tabrizi A; Mobasseri M; Tayebi Khosroshahi H; Heydarnejad M; Khalaj MR; Aghamohammadzadeh N
    Iran J Kidney Dis; 2012 Jan; 6(1):39-43. PubMed ID: 22218118
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Antihypertensive therapy in diabetes mellitus].
    Hess B
    Ther Umsch; 1999 Jan; 56(1):25-32. PubMed ID: 10067131
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Renal Effects of Sulodexide in Type 2 Diabetic Patients without Nephrotic Range Proteinuria.
    Yongwatana K; Supasyndh O; Satirapoj B
    J Diabetes Res; 2020; 2020():2984680. PubMed ID: 32851094
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Emerging trends for prevention and treatment of diabetic nephropathy: blockade of the RAAS and BP control.
    Hunsicker LG
    J Manag Care Pharm; 2004 Sep; 10(5 Suppl A):S12-7. PubMed ID: 15369420
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Thailand diabetes registry project: prevalence, characteristics and treatment of patients with diabetic nephropathy.
    Ngarmukos C; Bunnag P; Kosachunhanun N; Krittiyawong S; Leelawatana R; Prathipanawatr T; Plengvidhya N; Benjasuratwong Y; Suwanwalaikorn S; Deerochanawong C; Chetthakul T; Mongkolsomlit S; Rawdaree P
    J Med Assoc Thai; 2006 Aug; 89 Suppl 1():S37-42. PubMed ID: 17715832
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of addition of silymarin to renin-angiotensin system inhibitors on proteinuria in type 2 diabetic patients with overt nephropathy: a randomized, double-blind, placebo-controlled trial.
    Fallahzadeh MK; Dormanesh B; Sagheb MM; Roozbeh J; Vessal G; Pakfetrat M; Daneshbod Y; Kamali-Sarvestani E; Lankarani KB
    Am J Kidney Dis; 2012 Dec; 60(6):896-903. PubMed ID: 22770926
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adding a statin to a combination of ACE inhibitor and ARB normalizes proteinuria in experimental diabetes, which translates into full renoprotection.
    Zoja C; Corna D; Gagliardini E; Conti S; Arnaboldi L; Benigni A; Remuzzi G
    Am J Physiol Renal Physiol; 2010 Nov; 299(5):F1203-11. PubMed ID: 20719975
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Telmisartan and irbesartan therapy in type 2 diabetic patients treated with rosiglitazone: effects on insulin-resistance, leptin and tumor necrosis factor-alpha.
    Derosa G; Cicero AF; D'Angelo A; Ragonesi PD; Ciccarelli L; Piccinni MN; Pricolo F; Salvadeo SA; Ferrari I; Gravina A; Fogari R
    Hypertens Res; 2006 Nov; 29(11):849-56. PubMed ID: 17345784
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Kinins are involved in the antiproteinuric effect of angiotensin-converting enzyme inhibition in experimental diabetic nephropathy.
    Tschöpe C; Seidl U; Reinecke A; Riester U; Graf K; Schultheiss HP; Hilgenfeldt U; Unger T
    Int Immunopharmacol; 2003 Mar; 3(3):335-44. PubMed ID: 12639811
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.